Literature DB >> 25069791

The relationship of serum cortisol levels with depression, cognitive function and sleep disorders in chronic kidney disease and hemodialysis patients.

Baris Afsar1.   

Abstract

In the present study, the relationships between cortisol, cognitive function, depressive behavior, and sleep quality in chronic kidney disease (CKD) and hemodialysis (HD) patients was investigated. Patients underwent history taking, physical examination, biochemical analysis, 24-h urine collection (for CKD patients only), measurement of dialysis adequacy (for HD patients only), evaluation of cognitive function, depressive behavior and sleep quality. Among study participants 58 had creatinine clearance ≥60 mL/min/1.73 m(2) (Group 1), 41 had creatinine clearance between 30 and 59 mL/min/1.73 m(2) (Group 2), 25 had creatinine clearance between 15 and 29 mL/min/1.73 m(2) (Group 3) and 12 had creatinine clearance <15 mL/min/1.73 m(2) (Group 4). 38 patients were regular HD patients (Group 5). The cortisol levels in Group 1, 2, 3, 4 and 5 patients were 472.3 ± 138.4, 490.2 ± 214.3, 541.6 ± 172.8, 569.9 ± 101.0 and 637.8 ± 153.7 nmol/L, respectively (P < 0.0001 for trend). In both non-dialysis patient group and dialysis patients linear regression analysis showed that cortisol was independently related with Beck depression inventory (BDI) score (P: 0.013 and 0.001, respectively) but not with cognitive function and sleep quality. In conclusion serum cortisol levels were independently associated with depressive behavior both in CKD and HD patients but not with cognitive function and sleep quality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25069791     DOI: 10.1007/s11126-014-9307-5

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  23 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  An open label trial of C-1073 (mifepristone) for psychotic major depression.

Authors:  Joseph K Belanoff; Anthony J Rothschild; Frederick Cassidy; Charles DeBattista; Etienne-Emile Baulieu; Clifford Schold; Alan F Schatzberg
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

Review 3.  Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment.

Authors:  N Sonino; G A Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Neuropsychiatric complications of chronic kidney disease.

Authors:  Rory McQuillan; Sarbjit V Jassal
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.

Authors:  Allan H Young; Peter Gallagher; Stuart Watson; Dolores Del-Estal; Bruce M Owen; I Nicol Ferrier
Journal:  Neuropsychopharmacology       Date:  2004-08       Impact factor: 7.853

Review 7.  Glucocorticoid action networks and complex psychiatric and/or somatic disorders.

Authors:  George P Chrousos; Tomoshige Kino
Journal:  Stress       Date:  2007-06       Impact factor: 3.493

8.  Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.

Authors:  C B Nemeroff; E Widerlöv; G Bissette; H Walléus; I Karlsson; K Eklund; C D Kilts; P T Loosen; W Vale
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

9.  HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions.

Authors:  Masako Aihara; Itsuro Ida; Naoya Yuuki; Akihiko Oshima; Hiroshi Kumano; Keisuke Takahashi; Masato Fukuda; Noboru Oriuchi; Keigo Endo; Hiroshi Matsuda; Masahiko Mikuni
Journal:  Psychiatry Res       Date:  2007-06-22       Impact factor: 3.222

10.  Does metabolic syndrome have an impact on the quality of life and mood of hemodialysis patients?

Authors:  Baris Afsar; Rengin Elsurer; Siren Sezer; Nurhan F Ozdemir
Journal:  J Ren Nutr       Date:  2009-05-23       Impact factor: 3.655

View more
  3 in total

1.  Acute exercise during hemodialysis prevents the decrease in natural killer cells in patients with chronic kidney disease: a pilot study.

Authors:  Maria Isabel Fuhro; Gilson P Dorneles; Francini P Andrade; Pedro R T Romão; Alessandra Peres; Mariane B Monteiro
Journal:  Int Urol Nephrol       Date:  2017-11-13       Impact factor: 2.370

2.  Alexithymia, Phosphorus Levels, and Sleep Disorders in Patients on Hemodialysis.

Authors:  Đorđe Pojatić; Dajana Nikić; Ivana Tolj; Davorin Pezerović; Andrijana Šantić; Dunja Degmečić
Journal:  J Clin Med       Date:  2022-06-05       Impact factor: 4.964

3.  Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study.

Authors:  Md Rabiul Islam; Md Reazul Islam; Imtiaz Ahmed; Abdullah Al Moktadir; Zabun Nahar; Mohammad Safiqul Islam; Shelina Fatema Binte Shahid; Sheikh Nazrul Islam; Md Saiful Islam; Abul Hasnat
Journal:  SAGE Open Med       Date:  2018-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.